b
r
c
r
c
l
e
n
f
deciph
biolog
signal
pathway
make
use
converg
approach
includ
direct
gene
manipul
downstream
inform
process
intermedi
messeng
rna
protein
signal
small
moleculeshormon
metabolit
gene
manipul
particular
gene
deletioninvalid
one
wide
use
approach
determin
function
gene
product
present
major
advantag
select
alter
one
gene
structur
express
given
phenotyp
observ
gener
close
associ
gene
interest
product
hand
gene
delet
overexpress
induc
yet
revers
manner
control
experi
must
carri
wild
type
anim
development
compensatori
effect
may
taken
place
compar
manner
chensu
et
al
auwerx
et
al
brown
et
al
yang
et
al
chemic
biolog
approach
ie
method
use
chemic
tool
elucid
function
protein
given
signal
pathway
frontier
pharmacolog
chemistri
biophys
use
show
complementar
genet
approach
also
offer
possibl
transpos
small
molecul
tool
drug
patholog
issu
come
play
assess
protein
function
advantag
drawback
chemic
biolog
approach
mirror
imag
genom
approach
revers
effect
molecul
studi
live
individu
upon
cessat
molecul
administr
hand
molecul
rare
specif
given
target
protein
claim
select
compound
gener
follow
invers
relationship
extent
side
effect
wermuth
antibodi
particular
monoclon
antibodi
arisen
potenti
substitut
genet
chemic
biolog
approach
sens
exhibit
quasiexclus
select
protein
target
interrupt
treatment
lead
revers
effect
antibodi
offer
addit
possibl
target
interact
especi
larg
proteinprotein
interact
difficult
perturb
small
molecul
led
exponenti
develop
antibodi
antibodi
fragment
chame
et
al
nelson
reichert
wesolowski
et
al
therapeut
purpos
antibodi
power
tool
laboratori
research
develop
much
faster
small
chemic
molecul
see
thu
larg
use
valid
involv
protein
signal
transduct
pathway
potenti
target
drug
develop
hand
antibodi
intrins
limit
constrain
use
biolog
system
explor
except
antibodi
antibodi
fragment
cross
biolog
barrier
intestin
blood
brain
barrier
consequ
antibodi
must
inject
central
nervou
system
protein
reach
also
antibodi
reach
intracellular
target
protein
unless
cycl
plasma
membran
reason
chemic
biolog
approach
use
small
molecul
tool
drug
remain
use
valid
strategi
articl
review
exampl
small
chemic
molecul
use
neutral
small
signal
protein
chemokin
cytokin
reader
appreci
exampl
known
date
reason
neutral
molecul
discoveri
present
serendipit
specif
design
experiment
approach
enter
start
block
small
molecul
search
inhibit
proteinprotein
interact
focu
intracellular
compart
cancer
relat
interact
brain
function
explor
berg
arkin
well
arkin
well
mcclendon
blazer
neubig
review
focu
mainli
famili
small
signal
protein
chemokin
constitut
well
adapt
biolog
system
develop
neutral
small
molecul
exampl
cytokin
discuss
well
chemokin
small
secret
chemotact
cytokin
endow
multipl
activ
main
function
chemic
attract
leukocyt
also
contribut
regul
organ
develop
ontogeni
inflamm
chemotact
signal
given
chemokin
lead
egress
leukocyt
blood
circul
across
wall
small
blood
vessel
chemokin
produc
site
inflamm
cross
endotheli
cell
wall
remain
immobil
lumin
surfac
endothelium
circul
leukocyt
depend
chemokin
receptor
express
attract
direct
toward
inflam
site
along
chemotact
gradient
chemokin
addit
attract
cell
contribut
regul
gene
express
target
cell
help
control
cell
prolifer
apoptosi
instanc
angiogenesi
chemokin
also
subdivid
sever
function
group
depend
whether
express
constitut
induc
inflammatori
signal
also
capac
stimul
inhibit
angiogenesi
especi
tumor
vandercappellen
et
al
cxc
chemokin
particular
exert
angiogen
angiostat
activ
depend
presenc
elr
gluleuarg
motif
ntermin
portion
addison
et
al
import
regul
cell
migrat
therapeut
intervent
chemokin
system
includ
infecti
diseas
intraorgan
alert
system
possibl
lead
autoimmun
diseas
multipl
sclerosi
rheumatoid
arthriti
psoriasi
lupu
erythematosu
well
allerg
disord
asthma
inflammatori
bowel
diseas
transplant
reject
neuropathi
dermat
chemokin
known
chemokin
structur
fig
compris
ntermin
loop
region
threestrand
antiparallel
betasheet
form
typic
core
fold
chemokin
ctermin
alpha
helix
overlay
betasheet
cc
cxc
chemokin
compris
addit
two
disulfid
bridg
link
ntermin
domain
loop
separ
sheet
sheet
ntermin
domain
end
sheet
order
allow
gradient
form
vicin
site
releas
chemokin
bind
extracellular
matrix
compon
ie
neg
charg
glycosaminoglycan
gag
mean
posit
charg
amino
acid
posit
amino
acid
form
distinct
cluster
surfac
chemokin
depend
whether
chemokin
belong
cc
cxc
group
laguri
et
al
cxc
chemokin
group
gagbind
area
side
protein
interact
receptor
amara
et
al
santiago
et
al
murphi
et
al
mutat
posit
amino
acid
bind
gag
alter
chemokin
bind
receptor
amara
et
al
proudfoot
et
al
interact
heparan
sulfat
chang
equilibrium
bind
affin
chemokin
receptor
valenzuelafernandez
et
al
cc
group
chemokin
contrast
signific
overlap
receptor
bind
gagbind
area
case
instanc
influenc
receptor
subtypespecif
interact
chemokin
signal
g
protein
coupl
seven
transmembran
receptor
classifi
accord
chemokin
bind
cxcr
ccr
xcr
murphi
chemokin
receptor
famili
group
twenti
gproteincoupl
receptor
gpcr
cover
extrem
divers
physiolog
respons
gener
rule
structur
promiscu
gpcr
account
frequent
observ
problem
ligand
select
among
subtyp
reciproc
gpcr
ligand
particular
chemokin
group
small
chemic
famili
neutral
ligand
rather
receptor
may
allow
good
focu
subset
target
signal
pathway
along
sever
signal
protein
alcami
smith
colotta
et
al
pitti
et
al
rahaman
et
al
bezerra
et
al
bamia
et
al
de
moura
et
al
fili
et
al
funk
et
al
mueller
et
al
scola
et
al
chemokin
subject
natur
modul
concentr
protein
bind
fig
without
lead
typic
signal
murphi
alcami
graham
mckimmi
mantovani
et
al
murphi
et
al
graham
pruenster
et
al
protein
may
endogen
encod
modul
chemokin
function
express
exogen
sourc
like
pathogen
parasit
aim
escap
host
immun
system
see
natur
occur
scaveng
decoy
protein
act
interceptor
ie
intercept
receptorsthat
neutral
action
chemokin
shall
briefli
review
system
valid
concept
ligand
neutral
consid
approach
unnatur
neutral
besid
metabol
regul
hormon
peptid
product
enzymat
degrad
transport
mortier
et
al
captiv
aspect
respons
regul
scaveng
ligand
molecul
bind
modul
biolog
function
illustr
past
year
identif
endogen
receptorlik
structur
lead
convent
signal
respons
small
protein
ligand
rather
seem
contribut
blockad
elimin
colotta
et
al
colotta
et
al
bezerra
et
al
mantovani
et
al
mantovani
et
al
thelen
thelen
mantovani
et
al
bamia
et
al
bonecchi
et
al
de
moura
et
al
mueller
et
al
scola
et
al
receptorlik
molecul
solubl
colotta
et
al
de
moura
et
al
funk
et
al
membranebound
mantovani
et
al
scola
et
al
term
decoy
scaveng
protein
howev
serv
physiolog
well
pathophysiolog
function
decoy
protein
interleukin
colotta
et
al
de
moura
et
al
caput
et
al
rahaman
et
al
death
ligand
trail
bellail
et
al
pitti
et
al
activ
nfkbrank
simonet
et
al
khosla
complement
cain
monk
scola
et
al
gener
exhibit
ligand
select
andor
specif
chemokin
mantovani
et
al
graham
display
poor
ligand
select
three
possibl
four
endogen
protein
belong
structur
famili
gproteincoupl
receptor
bind
chemokin
limit
low
select
signal
toward
gproteindepend
pathway
keep
capac
intern
transport
bound
chemokin
across
plasma
membran
protein
darc
ccxckr
possibl
act
uptak
reuptak
protein
trap
ligand
intern
direct
toward
degrad
possibl
also
toward
transcytosi
protein
play
import
role
inflamm
develop
chemokineassoci
diseas
cancer
graham
mckimmi
mantovani
et
al
duffi
antigen
receptor
chemokin
darc
bind
cc
cxc
inflammatori
chemokin
well
homeostat
chemokin
gproteincoupl
receptorlik
protein
lack
capac
stimul
g
protein
darc
express
high
level
cell
membran
erythrocyt
shown
contribut
clear
circul
chemokin
darbonn
et
al
support
role
chemokin
clearanc
lack
darc
protein
associ
exagger
inflammatori
respons
lipopolysaccharid
lp
dawson
et
al
overexpress
protein
lead
diminish
angiogenesi
bonecchi
et
al
support
import
darc
exampl
differ
possibl
rout
follow
chemokinescytokin
presenc
neutral
macromolecul
rout
lead
signal
target
cell
express
chemokinecytokin
receptor
rout
use
either
endogen
pathogen
bind
chemokin
take
place
without
signal
event
may
either
lead
degrad
chemokin
transcytosi
rout
use
pathogen
express
solubl
protein
capabl
bind
chemokin
gener
moder
affin
select
prevent
normal
signal
immun
system
rout
neutral
molecul
prevent
chemokin
bind
glycosaminoglycan
result
effect
collaps
chemotact
gradient
abolish
leukocyt
attract
inflam
tissu
chemokin
clearanc
circul
mostli
associ
red
blood
cell
wild
type
mice
found
plasma
darc
mice
accordingli
mous
model
acut
lung
injuri
lpsinduc
polymorphonuclear
leukocyt
migrat
alveolar
space
elev
twofold
knockout
anim
reutershan
et
al
chemokin
sequest
function
darc
also
clinic
valid
preventingreduc
tumor
cell
growth
demonstr
breast
cancer
wang
et
al
darc
also
express
endotheli
cell
normal
condit
express
restrict
postcapillari
venul
fra
et
al
may
extend
type
blood
vessel
arteri
capillari
infect
inflamm
graft
reject
seger
et
al
gardner
et
al
endotheli
cell
darc
protein
serv
transport
allow
chemokin
transcytosi
thu
lead
effici
exposur
tissuederiv
inflammatori
chemokin
lumen
vessel
subsequ
leukocyt
recruit
extravas
pruenster
et
al
like
darc
exhibit
poor
select
toward
chemokin
bind
differ
chemokin
none
belong
cxc
group
cc
proinflammatori
molecul
implic
probabl
regul
inflamm
noteworthi
also
fact
darc
bind
ident
chemokin
bonecchi
et
al
express
lymphat
endotheli
cell
noninflam
skin
gut
lung
upon
inflamm
express
leukocyt
especi
invad
inflam
tissu
graham
mckimmi
contrast
darc
promot
chemokin
transcytosi
rather
contribut
degrad
direct
toward
endosom
predominantli
local
recycl
endosom
capabl
traffick
cell
surfac
absenc
ligand
presenc
ligand
rapidli
intern
chemokin
howev
chemokin
effect
retain
intracellularli
readili
dissoci
receptor
vesicl
acidif
chemokin
degrad
receptor
recycl
cell
surfac
fra
et
al
galliera
et
al
weber
et
al
like
physiolog
role
thu
clear
tissu
remain
chemokin
order
prevent
excess
respons
eventu
termin
inflammatori
respons
graham
mckimmi
support
lack
express
vivo
result
amplifi
chemokinemedi
inflammatori
respons
jamieson
et
al
martinez
de
la
torr
et
al
mice
show
high
level
inflammatori
chemokin
lymph
node
contrast
overexpress
reduc
leukocyt
respons
inflamm
model
nibb
et
al
result
deregul
express
chemokin
receptor
chemokin
cancer
role
carcinogenesi
propos
nibb
et
al
wu
et
al
due
capac
sequest
chemokin
protect
tumorigenesi
chemic
treatmentevok
skin
tumor
nibb
et
al
anoth
studi
report
reduc
intratumor
level
chemokin
consequ
inhibit
prolifer
invas
breast
cancer
cell
vitro
well
tumorigenesi
metastasi
vivo
wu
et
al
ccxckr
like
darc
deriv
gproteincoupl
structur
devoid
signal
capac
toward
g
protein
express
variou
organ
spleen
lymph
node
heart
kidney
placenta
trachea
brain
gosl
et
al
variou
cell
type
like
cell
immatur
dendrit
cell
stromal
cell
astrocyt
dorf
et
al
ciliat
bronchial
epitheli
cell
pulmonari
sarcoidosi
kriegova
et
al
endotheli
cell
surround
cancer
cell
tumor
feng
et
al
ccxckr
bind
homeostat
chemokin
control
traffick
naiv
cell
mediat
b
cell
helper
cell
migrat
gosl
et
al
townson
nibb
comerford
et
al
direct
toward
degrad
vitro
cell
express
ccxckr
deplet
larg
quantiti
chemokin
gosl
et
al
townson
nibb
comerford
et
al
inflamm
promot
signal
interleukin
tumor
necrosi
factor
interferon
ifn
gamma
attenu
ccxckr
mrna
level
support
potenti
link
interceptor
inflamm
vivo
particular
mice
harbour
ccxckr
transfect
xenograft
reduc
tumor
growth
neovascular
metastasi
detect
feng
et
al
also
clinic
studi
breast
cancer
show
natur
level
ccxckr
express
correl
longer
surviv
patient
feng
et
al
capac
gproteincoupl
receptor
endocytos
togeth
ligand
make
like
least
behav
interceptor
express
exampl
regul
cell
respond
antiinflammatori
lipid
modif
repres
mechan
chemokin
trap
inflamm
termin
ariel
et
al
second
receptor
name
anoth
exampl
atyp
receptor
inde
although
receptor
sequenc
contain
canon
dri
sequenc
requir
coupl
receptor
g
protein
attempt
detect
signal
g
protein
activ
mapkinas
stimul
unsuccess
date
balabanian
et
al
burn
et
al
damblychaudier
et
al
except
one
report
signal
akt
may
result
betaarrestin
recruit
kalatskaya
et
al
luker
et
al
zabel
et
al
whichev
way
signal
appear
import
develop
particular
heart
valv
format
sierro
et
al
stabil
cell
adhes
migrat
toward
gradient
dambl
chaudier
et
al
boldajipour
et
al
develop
zebrafish
sensori
system
format
sensori
organ
later
line
requir
long
distanc
migrat
primordi
germ
cell
damblychaudier
et
al
boldajipour
et
al
show
migrat
germ
cell
involv
chemokinet
respons
mediat
lead
migrat
germ
cell
direction
migrat
provid
trail
cell
express
second
receptor
prevent
backward
migrat
deplet
rear
migrat
group
cell
consist
mazzinghi
et
al
report
human
renal
progenitor
cell
use
receptor
transendotheli
migrat
major
contributor
cell
adhes
endotheli
cell
progenitor
cell
surviv
mazzinghi
et
al
enhanc
adhes
also
clearli
establish
prostat
cancer
cell
togeth
improv
cell
surviv
invas
case
report
contribut
physiolog
respons
could
chemokin
intercept
termin
subsequ
migratori
respons
least
modul
inde
show
significantli
higher
capac
increas
cellassoci
luker
et
al
anoth
probabl
physiolog
function
relat
capac
heterodimer
sierro
et
al
levoy
et
al
detect
bioluminescenceor
fluorescenceenergi
transfer
heterolog
express
system
recent
work
levoy
et
al
shown
exhibit
appar
paradox
effect
interf
respons
inde
reduc
respons
low
concentr
leav
respons
high
concentr
unchang
compar
alon
effect
also
detect
isol
human
lymphocyt
presenc
cell
express
render
doserespons
relationship
steeper
expect
law
mass
action
net
result
interfer
convers
respons
almost
noth
type
respons
sierro
et
al
levoy
et
al
trigger
versu
nontrigg
dose
differ
threeto
fivefold
physiolog
effect
support
concept
open
structur
demonstr
heterodimer
model
behavior
chemokin
scaveng
could
interest
discrimin
among
direct
receptorreceptor
interact
indirect
effect
regul
level
chemokin
would
avail
pathogen
virus
bacteria
parasit
set
sever
strategi
escap
host
detect
defenc
system
use
cytokin
chemokin
signal
molecul
receptor
ligand
infect
host
cell
chitni
sharma
hugh
nelson
also
block
cytokin
signal
produc
antagonist
damon
et
al
allow
escap
alert
system
redirect
benefit
mcfadden
et
al
sozzani
et
al
alcami
mantovani
et
al
rosenkild
andreasen
carbonetti
parasit
leishmania
infect
macrophag
exampl
express
function
chemokin
receptor
use
chemoreceptor
promot
chemokinesi
toward
chemokineproduc
macrophag
lead
effici
leishmania
intern
roychoudhuri
et
al
take
place
efficaci
immun
respons
set
clear
pathogen
second
exampl
taken
bacterium
bordetella
pertussi
pathogen
report
delay
neutrophil
recruit
slow
chemokin
product
host
andreasen
carbonetti
product
pertussi
toxin
well
known
inhibitor
gi
protein
mediat
signal
also
third
illustr
human
herpesviru
produc
chemokin
bind
modifi
internalizationrecycl
fate
catuss
et
al
catuss
et
al
inde
varianc
chemokin
agonist
drive
receptor
toward
clathrinmedi
endocytosi
delay
long
last
caveolinlink
pathway
combin
fact
recogn
darc
viral
chemokin
thu
facilit
clearanc
chemokin
longer
activ
receptor
remain
capabl
trap
interceptor
relev
present
articl
neutral
molecul
produc
virus
multicellular
pathogen
use
neutral
immun
respons
host
sever
articl
review
describ
product
virus
solubl
protein
abl
bind
chemokin
sometim
simultan
cytokin
interferon
gamma
tumor
necrosi
factor
mcfadden
et
al
murphi
alcami
rosenkild
mantovani
et
al
implic
host
immun
respons
pathogen
two
major
mechan
action
depict
inhibit
cytokinecytokin
receptor
interact
inhibit
cytokineextracellular
matrix
interact
mcfadden
et
al
associ
improv
cytokin
clearanc
elimin
andor
degrad
biolog
activ
scaveng
molecul
solubl
protein
often
mimick
extracellular
bind
domain
host
cytokin
receptor
may
also
membranebound
protein
like
decoy
receptor
mimick
chemokin
receptor
contain
solubl
portion
repres
solubl
protein
inhibit
interact
chemokin
glycosaminoglycan
gag
extracellular
matrix
produc
rabbitinfect
myxoma
viru
bind
interferon
gamma
togeth
chemokin
cc
cxcand
cgroup
lalani
et
al
herpesviru
homodimer
protein
glycoprotein
g
also
belong
group
solubl
protein
inhibit
chemokin
bind
gag
van
berkel
et
al
martin
et
al
exhibit
origin
tridimension
structur
resembl
chemokin
receptor
mechan
neutral
immun
system
may
twofold
one
hand
gag
well
known
contribut
set
mainten
chemokin
gradient
close
site
product
inhibit
chemokin
bind
gag
might
thu
result
chemokin
gradient
collaps
alter
immun
respons
could
deriv
could
attenu
signal
intens
unsuit
even
absenc
leukocyt
target
hand
larg
size
solubl
chemokin
bind
protein
could
hinder
interact
chemokin
receptor
thu
although
target
domain
chemokin
gagbind
domain
remaind
larg
solubl
protein
might
simultan
prevent
interact
cognat
chemokin
receptor
use
small
molecul
mimick
effect
gagbind
protein
would
help
determin
mechan
action
like
take
place
anoth
exampl
solubl
protein
produc
parasit
highlight
recent
research
develop
tick
bloodsuck
parasit
transmit
spirochet
borrelia
burgdorferi
respons
lyme
diseas
hirschfeld
et
al
hajnicka
et
al
gueraudearellano
huber
behera
et
al
vancova
et
al
deruaz
et
al
order
surviv
tick
attach
remain
feed
host
sever
daysweek
particular
hostparasit
interact
absenc
inflammatori
respons
tick
investig
sever
group
realiz
parasit
produc
antihaemostat
antiinflammatori
immunomodulatori
substanc
secret
host
waxman
et
al
valenzuela
et
al
antichemokin
molecul
act
hajnicka
et
al
vancova
et
al
detect
although
ident
elucid
use
express
clone
strategi
group
proudfoot
identifi
famili
small
protein
evasin
similar
solubl
viral
chemokin
bind
protein
recogn
bind
chemokin
variou
degre
select
intercept
signal
host
immun
antiinflammatori
system
frauenschuh
et
al
deruaz
et
al
three
identifi
evasin
bind
cc
cxc
chemokin
fourth
one
still
without
known
ligand
interest
small
protein
resid
extrem
efficaci
delud
immun
system
small
size
amino
acid
inspir
search
chemokin
neutral
motif
potenti
becom
drug
second
gener
mode
action
pathogen
reminisc
intercept
receptor
describ
human
mous
cytomegaloviru
kaposiassoci
herpesviru
capripoxviru
produc
seven
transmembran
segment
protein
analog
gproteincoupl
receptor
alcami
rosenkild
protein
express
surfac
infect
cell
act
similarli
darc
ccxckr
decoy
protein
intern
chemokin
drive
toward
degrad
soon
discoveri
differ
chemokin
number
receptor
grew
member
belong
gproteincoupl
receptor
famili
note
one
given
chemokin
may
activ
sever
receptor
subtyp
chemokin
instanc
activ
two
receptor
chemokin
activ
three
receptor
hand
larg
number
chemokin
may
activ
singl
receptor
subtyp
case
activ
activ
belperio
et
al
white
et
al
colvin
et
al
well
mani
receptor
review
well
et
al
question
aros
receptor
chemokin
target
deciph
physiolog
signal
pathway
predict
therapeut
approach
diseas
treatment
mani
research
group
could
help
solv
problem
show
despit
chemokin
cytokin
cooper
increas
inflammatori
respons
knock
neutral
one
chemokin
chemokin
receptor
induc
signific
attenu
inflamm
see
tabl
sever
chemokin
gene
disrupt
result
clear
effect
instanc
knock
reduc
inflammatori
respons
virus
influenza
cytomegaloviru
salazarmath
et
al
similarli
knockout
approach
indic
import
receptor
chemoattract
neural
progenitor
inflam
neural
site
belmadani
et
al
glial
cell
activ
elhag
et
al
thymu
develop
liu
et
al
haematopoiesi
nagasawa
et
al
convinc
result
also
obtain
use
protein
antibodi
neutral
chemokin
ligand
luca
mc
fadden
group
exploit
neutral
effect
myxoma
viru
solubl
protein
reduc
postop
respons
murin
model
tissu
engraft
bedard
et
al
show
intraven
inject
protein
bind
type
chemokin
see
section
rat
angioplastyinduc
injuri
diminish
atherosclerosi
restenosi
good
agreement
phenotyp
mice
gosl
et
al
report
prevent
renal
allograft
reject
bedard
et
al
reduct
aortic
allograft
vasculopathi
inhibit
chemokinemedi
respons
final
newli
identifi
evasin
protein
tick
also
display
potent
antiinflammatori
properti
vivo
anim
model
deruaz
et
al
bind
significantli
attenu
recruit
proinflammatori
cell
phorbol
esterinflam
skin
mice
fibrosi
bleomycininduc
lung
injuri
recogn
mous
homolog
kc
well
inhibit
neutrophil
chemotaxi
vitro
well
neutrophil
recruit
periton
caviti
mice
model
bsainduc
arthriti
chemokin
directli
implic
mani
physiolog
process
includ
surveil
organ
integr
elimin
damag
cell
tissu
host
defenc
pathogen
end
recruit
adapt
cell
type
site
intervent
need
promot
control
reaction
gener
associ
limit
inflamm
abnorm
condit
inflammatori
respons
escap
control
thu
lead
patholog
state
inflammatori
bowel
diseas
multipl
sclerosi
probabl
alzheim
diseas
among
other
case
abnorm
elev
level
chemokin
overexpress
receptor
lead
perman
recruit
immun
cell
tissu
damag
compar
manner
abnorm
recognit
antigen
initi
autoimmun
diseas
myasthenia
gravi
lupu
erythematosu
type
diabet
rheumatoid
abnorm
elev
level
chemokin
detect
matin
et
al
kong
et
al
wang
et
al
cytokin
chemokin
system
also
use
cancer
cell
promot
cell
prolifer
tumor
surviv
neovascular
establish
metastas
distant
nonrandom
place
vandercappellen
et
al
chemokin
also
contribut
tissu
develop
nagasawa
et
al
mahabaleshwar
et
al
raz
mahabaleshwar
form
gradient
morphogen
migrat
cell
tabl
summar
effort
made
investig
role
variou
chemokin
use
approach
target
chemokin
directli
possibl
two
major
approach
name
gene
disrupt
antichemokin
antibodi
gener
lead
converg
observ
although
phenomenon
rare
studi
use
two
approach
delet
one
receptor
receptor
allel
found
human
associ
protect
hiv
infect
human
samson
et
al
kindberg
et
al
lim
et
al
delet
second
receptor
receptor
result
protect
excess
respons
system
inflamm
mous
model
gerard
et
al
delet
ligand
result
weaker
inflammatori
respons
viral
pathogen
cook
et
al
delet
rant
reduc
glial
cell
inflammatori
respons
elhag
et
al
therefor
absenc
perfect
match
chemokin
receptor
caus
difficulti
encount
signal
pathway
trace
molecul
target
function
one
receptor
systemat
match
effect
molecul
target
ligand
horuk
rather
knock
chemokin
chemokin
receptor
gene
neutral
antibodi
rapidli
obtain
use
particular
chemokin
chemokin
small
protein
highli
stabl
structur
fig
render
amen
develop
neutral
antibodi
tabl
case
instanc
neutral
antibodi
allow
function
role
chemokin
autocrin
prolifer
leukemia
cell
bore
et
al
izikson
et
al
aldinucci
et
al
demonstr
well
neuroinflamm
model
multipl
sclerosi
glass
et
al
interest
note
although
bind
subset
chemokin
receptor
neutral
effect
specif
express
cell
type
antibodi
use
demonstr
contribut
autocrin
activ
periton
macrophag
format
periton
adhes
constitut
complic
viscer
surgeri
inflamm
hoshino
et
al
also
antibodi
block
antiapoptot
prolif
effect
correspond
tumorderiv
cell
line
obtain
lung
melanoma
breast
ovarian
leukemia
cancer
levina
et
al
besid
function
immun
system
role
chemokin
cancer
initi
progress
well
tumor
surviv
confirm
neutral
antibodi
strategi
henc
antibodi
chemokin
chemokin
receptor
block
tumor
growth
andor
migrat
well
invas
variou
exampl
may
given
like
antibodi
ovarian
breast
cancer
muller
et
al
scotton
et
al
kwong
et
al
ii
lung
cancer
wang
et
al
iii
cell
line
pancreat
colon
cancer
meijer
et
al
iv
vaday
et
al
ovarian
cancer
levina
et
al
v
thyroid
tumor
cell
sancho
et
al
studi
proteinprotein
interact
import
understand
major
regulatori
pathway
especi
intracellular
compart
reach
neutral
antibodi
difficulti
associ
studi
proteinprotein
interact
time
interact
partner
intracellular
thu
easili
access
biophys
pharmacolog
manipul
also
proteinprotein
interact
gener
involv
contact
area
much
larger
small
molecul
contact
area
addit
quit
featureless
term
number
attach
point
exploit
medicin
chemist
develop
small
molecul
high
affin
follow
small
molecul
bind
modest
affin
frequent
hardli
compet
effici
inhibit
interact
two
protein
still
favour
case
exist
neutral
protein
function
obtain
small
molecul
arkin
well
arkin
arkin
moasser
blazer
neubig
approach
work
question
relat
mode
action
small
molecul
must
address
order
gener
principl
extend
approach
specif
case
differ
mechan
ligand
neutral
numer
divers
term
chemic
biolog
aim
thu
develop
small
chemic
molecul
block
function
protein
ligand
shall
discuss
molecul
inhibit
synthesi
matur
releas
protein
ligand
molecul
modul
catabol
alreadi
review
elsewher
foxwel
et
al
vergot
et
al
mortier
et
al
rather
focu
small
organ
molecul
bind
protein
ligand
prevent
signal
four
main
mode
action
encount
fig
small
molecul
competit
bind
site
receptor
ii
small
molecul
alter
quaternari
structur
protein
ligand
iii
protein
ligand
undergo
structur
chang
regul
activ
small
molecul
alter
tertiari
structur
protein
ligand
iv
small
molecul
interfer
ligand
bioavail
differ
mode
chemokinecytokin
neutral
illustr
method
identifi
discuss
mechan
action
valid
berg
arkin
well
arkin
blazer
neubig
may
extend
chemokin
neutral
base
upon
structurefunct
relationship
studi
mani
exampl
peptid
mimick
receptor
domain
act
inhibitor
avail
famili
chemokin
receptor
import
extracellular
part
chemokin
receptor
zoffmann
et
al
duma
et
al
particular
aminotermin
domain
ligandreceptor
interact
extens
document
blanpain
et
al
gayl
et
al
fig
superimposit
peptid
backbon
cc
cxc
chemokin
group
show
canon
three
dimension
structur
bannert
et
al
fong
et
al
rajagopalan
rajarathnam
prado
et
al
veldkamp
et
al
led
identif
peptid
fragment
capabl
bind
chemokin
manner
thought
mimic
mode
interact
chemokin
receptor
peptid
fragment
correspond
ntermin
residu
mayer
stone
ye
et
al
clubb
et
al
mizou
et
al
kokkoli
et
al
interact
respect
millimolar
micromolar
affin
three
exampl
interact
area
chemokin
locat
helic
turn
nloop
hairpin
domain
region
greatest
flexibl
structur
variabl
chemokin
mizou
et
al
peptid
use
investig
vitro
vivo
function
chemokin
discoveri
howev
suggest
neutral
antibodiesbas
approach
tabl
possibl
tool
inhibit
chemokin
function
pave
way
find
high
affin
peptid
capabl
neutral
chemokin
one
approach
start
natur
peptid
target
chemokin
illustr
work
evasin
deruaz
et
al
describ
although
peptid
natur
evasin
immunogen
least
secret
feed
tick
thu
expect
repres
valuabl
scaffold
studi
make
analog
use
nonpeptid
drug
anoth
approach
consist
identifi
new
chemokin
bind
molecul
collect
peptid
peptidomimet
burger
pele
peptid
peptidomimet
may
either
exhibit
select
toward
singl
chemokin
contrast
poorli
discrimin
among
chemokin
pele
eizenberg
vaizelohayon
us
patent
peptid
bkt
identifi
surfac
plasmon
reson
elisa
current
clinic
phase
neutropenia
anemia
chemokin
neutral
ligand
may
also
peptid
screen
campaign
academ
librari
small
molecul
boeglin
et
al
hibert
design
use
fluoresc
reson
energi
transfer
assay
vollmer
et
al
valenzuelafernandez
et
al
order
identifi
inhibitor
interact
chalcon
molecul
chalcon
found
effect
k
nm
inhibit
bind
signal
includ
chemotaxi
vitro
vivo
hachethaa
et
al
molecul
howev
unabl
block
cell
fusion
vitro
model
chanel
et
al
hiv
entri
propos
model
chalcon
bind
chemokin
rather
receptor
could
demonstr
use
tryptophan
fluoresc
microcalorimetri
reminisc
earlier
studi
describ
natur
deriv
chalcon
flavon
baicalin
isol
scutellaria
baicalensi
bind
chemokin
although
affin
four
order
magnitud
lower
li
et
al
compound
chalcon
modestli
inhibit
signal
chemokin
structur
subgroup
activ
least
micromolar
concentr
rang
final
chalcon
compound
show
efficaci
vivo
mous
model
allerg
hypereosinophil
airway
inflamm
power
neutral
antibodi
either
hachethaa
et
al
although
structur
chemokinechalcon
solv
molecular
model
preliminari
nmr
data
c
veldkamp
milwauke
univers
person
commun
support
idea
chalcon
bind
chemokin
area
chemokin
receptorderiv
peptid
ie
groov
delin
nloop
hairpin
chemokin
fig
yet
whether
chalcon
perturb
state
chemokin
oligomer
remain
open
question
chalcon
molecul
report
act
inhibitor
allerg
inflammatori
diseas
meng
et
al
question
whether
chalcon
backbon
act
chemic
platform
biolog
activ
molecul
open
mechan
action
molecul
vivo
might
reli
multipl
interact
differ
target
protein
exampl
neutral
small
molecul
illustr
flexibl
region
small
protein
ligand
target
high
affin
molecul
bind
proteinprotein
interfac
poorli
druggabl
adjust
structur
accommod
ligand
arkin
well
thano
et
al
receptor
mediat
thelper
cell
matur
drug
target
transplant
reject
waldmann
oshea
berard
et
al
autoimmun
diseas
schippl
martin
ligand
kda
four
helix
bundl
protein
promot
cell
growth
drug
design
program
aim
mimick
part
bind
peptidomimet
molecul
discov
tilley
et
al
molecul
could
inhibit
bind
receptor
micromolar
affin
care
character
mode
action
led
identif
receptor
receptor
protein
emerson
et
al
detail
structur
analysi
interact
particular
use
xray
crystallographi
nmr
arkin
et
al
describ
detail
bind
area
small
chemic
compound
bind
pocket
preexist
absenc
word
bind
area
complex
result
adapt
local
protein
fold
around
chemic
particular
case
illustr
difficulti
use
structur
empti
bind
site
priori
predict
structur
bind
howev
optim
compound
use
xray
crystallographi
complex
fragmentbas
approach
tether
techniqu
allow
affin
bind
molecul
lower
ten
nanomolar
raimundo
et
al
thano
et
al
chemokin
present
brain
glial
cell
well
neuron
rosten
et
al
concord
known
role
peripheri
chemokin
regul
inflamm
contribut
brain
immun
neuroprotect
cartier
et
al
glass
et
al
madrig
et
al
omari
et
al
also
involv
progenitor
cell
migrat
toward
brain
tumor
magg
et
al
particip
brain
develop
neuron
cell
differenti
zou
et
al
park
et
al
even
distribut
neuron
neuromodul
modifi
releas
neurotransmitt
neuropeptid
rosten
et
al
find
togeth
develop
pharmacolog
tool
chemokin
receptor
offer
possibl
better
studi
chemokin
signal
brain
agonist
antagonist
receptor
also
small
neutral
molecul
direct
chemokin
could
extrem
valuabl
particular
cross
blood
brain
barrier
bbb
reach
target
cytokin
one
exampl
convers
chemokin
agonist
ligand
antagonist
vergot
et
al
chalcon
molecul
mention
probabl
good
pharmacolog
agent
studi
neuron
toxic
associ
catabol
anoth
applic
potenti
neutral
ligand
exemplifi
effect
antibodi
administ
fight
leukocyt
infiltr
take
place
brain
result
virusdriven
product
mice
infiltr
follow
destruct
myelin
appear
neurolog
impair
glass
et
al
antibodi
significantli
decreas
macrophag
accumul
brain
demyelin
neutraligand
thu
prove
use
investig
incid
multipl
sclerosi
chemokin
show
natur
propens
form
dimer
oligom
depend
medium
composit
veldkamp
et
al
biochem
environ
particular
glycosaminoglycan
crown
et
al
interact
chemokin
receptor
veldkamp
et
al
homodimerizationoligomer
well
establish
cc
chemokin
blain
et
al
jin
et
al
proudfoot
et
al
heterodimer
also
experiment
support
instanc
heterodim
crown
et
al
function
consequ
homolog
heterolog
interact
well
understood
oligomer
process
may
interest
interfer
attempt
neutral
chemokin
action
fig
inde
cc
chemokin
dimer
correspond
quaternari
structur
interact
receptor
residu
critic
receptor
bind
buri
dimer
jin
et
al
mutat
made
abolish
dimer
proudfoot
et
al
jin
et
al
case
could
demonstr
certain
respons
particular
leukocyt
attract
vivo
abolish
select
suppress
certain
respons
leav
respons
unaffect
reminisc
previous
describ
multipl
activ
state
gproteincoupl
receptor
differenti
activ
distinct
agonist
modul
alloster
effector
maillet
et
al
prevent
dimer
format
per
se
suffici
block
chemoattract
vivo
mechan
action
interceptor
herpesviru
probabl
exquisit
optim
decoy
receptor
bind
two
monom
per
homodim
alexand
et
al
thu
even
though
recogn
bind
gagbind
domain
aptitud
dissolv
dimer
thu
like
repres
mechan
inhibit
signal
vivo
handel
et
al
case
cxc
chemokin
dimer
also
take
place
spontan
dimer
structur
differ
cc
chemokin
dimer
residu
import
receptor
interact
buri
dimer
cxc
chemokin
thu
interact
receptor
either
monom
dimersoligom
varianc
happen
cc
chemokin
interact
receptor
demonstr
cxc
chemokin
receptor
may
respons
chemokin
dimer
veldkamp
et
al
tyrosin
sulfat
ntermin
domain
tyrosin
inde
key
determin
receptormedi
dimer
format
sinc
sulfat
tyrosin
interact
monom
sulfat
tyrosin
interact
second
monom
two
line
evid
support
import
dimer
signal
amino
acid
involv
interact
heparan
sulfat
heparan
sulfat
thu
neg
affect
chemotaxi
vitro
murphi
et
al
ii
tether
monom
obtain
perman
dimer
result
partial
loss
function
perman
dimer
inde
show
unalt
capac
promot
intracellular
calcium
elev
express
cell
longer
capabl
trigger
vitro
chemotaxi
veldkamp
et
al
although
result
yet
total
interpret
term
structurefunct
relationship
modul
chemokin
oligomer
repres
promis
way
chang
cellular
respons
possibl
import
consequ
vivo
unsatur
heparin
disaccharid
use
perturb
dimer
structur
murphi
et
al
plausibl
start
chemic
platform
exploit
virtual
experiment
screen
collect
molecul
chemokin
dimer
could
lead
discoveri
neutral
molecul
mechan
action
would
prevent
dimer
format
critic
step
kind
project
would
definit
primari
secondari
assay
allow
qualit
quantit
descript
new
compound
effect
produc
respons
pathogen
tolllik
receptor
activ
promot
express
mani
immun
system
effector
includ
cytokin
chemokin
balkwil
recruit
leukocyt
site
inflamm
product
excess
chronic
inflamm
develop
rheumatoid
arthriti
crohn
diseas
sever
asthma
psoriasi
diseas
promin
role
demonstr
antiinflammatori
therapi
develop
base
inhibit
either
product
neutral
foxwel
et
al
neutral
monoclon
antibodi
etanercept
infliximab
adalimumab
led
success
treatment
rheumatoid
arthriti
show
neutral
antibodi
prove
valuabl
acut
also
chronic
human
diseas
yet
two
problem
remain
sever
run
antibodi
optim
human
use
mode
administr
associ
dose
difficulti
elev
cost
treatment
motiv
search
altern
therapeut
tool
search
small
molecul
collect
combinatori
fragment
capabl
inhibit
bind
receptor
et
al
discov
small
molecul
inhibitor
exhibit
micromolar
affin
constant
tri
identifi
xray
crystallographi
bind
site
small
molecul
larg
trimer
structur
author
realiz
soak
crystal
led
destruct
crystal
complex
obtain
reveal
mode
action
small
molecul
antagonist
dissoci
trimer
quaternari
structur
inact
inhibitorbound
dimer
stoichiometri
one
molecul
per
dimer
et
al
berg
illustr
one
mode
action
small
molecul
inhibitor
follow
descript
monom
failur
signal
handel
et
al
could
appli
famili
chemokin
protein
use
detect
quaternari
structur
primari
screen
protein
ligand
undergo
tertiari
structur
chang
regul
activ
small
molecul
prevent
activ
conform
solubl
protein
may
undergo
three
dimension
structur
chang
either
spontan
regul
manner
monod
et
al
mechan
pathogenesi
dobson
lymphotactin
chemokin
unusu
properti
first
contrast
chemokin
structur
stabil
singl
disulfid
bridg
second
singular
properti
exist
two
unrel
protein
fold
kuloglu
et
al
tuinstra
et
al
one
two
protein
fold
resembl
canon
chemokin
structur
antiparallel
one
carboxi
termin
helix
conform
bind
activ
receptor
interact
glycosaminoglycan
second
protein
fold
exhibit
antiparallel
helix
tuinstra
et
al
second
structur
bind
glycosaminoglycan
high
affin
unabl
activ
receptor
exampl
uniqu
date
field
protein
protein
ligand
gener
question
extrem
case
gener
field
chang
protein
conform
equilibrium
tackl
mani
differ
laboratori
mani
differ
regulatori
protein
select
new
pharmacolog
tool
activ
drug
ligand
would
stabil
glycosaminoglycan
bind
state
could
reveal
neutral
molecul
capabl
modul
acut
allograft
reject
respons
attenu
inflammatori
bowel
diseas
boismenu
et
al
middel
et
al
two
exampl
mucos
immun
lymphotactin
involv
chemokin
activ
gproteincoupl
receptor
recruit
leukocyt
organogenesi
immunosurveil
inflamm
import
compon
process
format
chemotact
gradient
immobil
chemokin
extracellular
matrix
cell
particular
glycosaminoglycan
analysi
role
play
glycosaminoglycan
carri
use
mutant
cc
proudfoot
et
al
cxcxcl
peterson
et
al
sadir
et
al
johnson
et
al
ali
et
al
jin
et
al
chemokin
devoid
key
residu
known
bind
neg
charg
sugar
moieti
suppress
gag
interact
chemokin
found
abolish
leukocyt
recruit
vivo
inject
intraperiton
although
vitro
chemotaxi
alter
import
interact
highlight
show
gagbind
mutant
chemokin
block
action
wild
type
chemokin
normal
anim
well
murin
model
diseas
ali
et
al
braunersreuth
et
al
pathogen
also
target
gagbind
domain
chemokin
prevent
effect
mention
section
avoid
strategi
poorli
select
protein
myxoma
viru
protein
herpesviru
glycoprotein
ectromelia
viru
neutral
chemokin
upon
bind
gagbind
domain
like
consequ
high
local
concentr
chemokin
give
rise
velcro
effect
reduc
gradient
disrupt
therefor
leukocyt
attract
longer
take
place
although
small
chemic
molecul
target
gagbind
domain
chemokin
describ
portion
protein
valid
chemic
biolog
approach
noteworthi
disaccharid
use
solv
structur
form
complex
heparinderiv
sugar
shaw
et
al
could
use
start
block
drug
design
interestingli
small
molecul
surfen
first
use
excipi
drug
formula
also
identifi
heparin
neutral
molecul
hunter
hill
antibacteri
trypanocid
activ
could
use
lower
excess
heparan
sulfateinvolv
interact
schuksz
et
al
mani
articl
report
either
genet
manipul
receptor
chemokin
develop
pharmacolog
agent
lead
select
alter
subset
respons
seri
possibl
respons
one
consequ
depend
desir
properti
molecul
develop
research
diseas
treatment
prefer
ligand
receptor
ligand
ligand
need
valid
experiment
inde
chemokin
activ
member
famili
gproteincoupl
receptor
gpcr
known
exhibit
signific
level
around
spontan
isomer
toward
activ
conform
lefkowitz
et
al
b
leur
et
al
palanch
et
al
alewijns
et
al
claeysen
et
al
lecat
et
al
spontan
activ
gpcr
well
establish
physiolog
role
adan
arrang
et
al
like
control
neurotransmitt
threlfel
et
al
hormon
benshlomo
et
al
releas
relat
higher
order
behavior
fioravanti
et
al
regul
apoptosi
lau
et
al
spontan
activ
chemokin
receptor
also
exist
herpesvirusencod
receptor
activ
link
transform
effect
burger
et
al
holst
et
al
ligand
gpcr
almost
never
behav
neutral
molecul
antagonist
either
weak
partial
agonist
increas
level
receptor
activ
call
invers
agonist
capabl
diminish
level
spontan
activ
receptor
small
molecul
neutral
ligand
may
complement
tool
palett
pharmacologist
sinc
expect
leav
spontan
activ
receptor
unchang
four
prefer
way
identifi
small
molecul
modul
proteinprotein
interact
elisa
assay
fluoresc
reson
energi
transfer
fret
assay
fluoresc
anisotropi
berg
surfac
plasmon
reson
design
gener
strategi
order
find
fluoresc
probe
bind
solubl
protein
fluoresc
anisotropi
strategi
involv
four
step
synthesi
librari
fluoresc
compound
use
known
chemic
scaffold
exhibit
low
specif
molecul
organ
around
gener
gpcrprefer
chemic
scaffold
derivat
charg
hydrophil
hydrophob
moieti
bear
lissamin
fluorophor
end
space
arm
screen
librari
fluoresc
molecul
fluoresc
anisotropi
measur
order
success
fish
one
fluoresc
probe
least
techniqu
allow
set
mix
read
assay
readili
pinpoint
probe
interact
protein
character
bind
properti
probe
order
fulfil
desir
requir
ie
neutral
bind
ligand
receptor
inhibit
oligomer
inhibit
bind
gag
select
desir
optim
screen
assay
screen
librari
unlabel
druglik
molecul
identifi
high
affin
molecul
use
chemic
biolog
purpos
gener
kind
drug
discoveri
approach
particular
univers
laboratori
highli
desir
increas
amount
screen
data
lead
larg
scale
chemoinformat
bioinformat
includ
data
transcript
analys
proteom
schadt
et
al
weill
rognan
develop
complex
network
model
case
system
biolog
order
establish
train
set
interact
network
predict
use
model
predict
molecul
toxic
metabol
bioavail
pattern
biolog
activ
